VX12-809-105: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygo

Project: Research project

Project Details

StatusFinished
Effective start/end date12/10/1312/31/16

Funding

  • Vertex Pharmaceuticals Incorporated (VX12-809-105)